Inactive Instrument

Kolon TissueGene, Inc.

Equities

A950160

KR8840120008

Kolon TissueGene, Inc. announced that it expects to receive KRW 47.753604 billion in funding from Kolon Corporation

May 23, 2024

Kolon TissueGene, Inc. announced a private placement to issue 762,350 shares at an issue price of KRW 62,640 for the gross proceeds of KRW 47,753,604,000 on May 23, 2024. The transaction will include participation from returning investor Kolon Corporation. The transaction has been approved by shareholder, restricted to a hold period and is expected to close on May 30, 2024.

Latest news about Kolon TissueGene, Inc.

Kolon TissueGene, Inc. announced that it has received $34.999709 million in funding	05/06	CI
Kolon TissueGene, Inc. announced that it has received KRW 47.753604 billion in funding from Kolon Corporation	30/05	CI
Kolon TissueGene, Inc. announced that it expects to receive KRW 47.753604 billion in funding from Kolon Corporation	23/05	CI
Kolon TissueGene, Inc. announced that it expects to receive $34.999709 million in funding	23/05	CI
Kolon TissueGene, Inc. announced that it has received $30.000024 million in funding	15/23/15	CI
Kolon TissueGene, Inc. announced that it has received KRW 39.999032395 billion in funding from Kolon Corporation	10/23/10	CI
Kolon TissueGene, Inc. announced that it expects to receive $30.000024 million in funding	09/23/09	CI
Kolon TissueGene, Inc. announced that it expects to receive KRW 30 million in funding from Kolon Corporation	21/22/21	CI
Kolon TissueGene, Inc. announced that it has received KRW 33 billion in funding from a group of investors	07/22/07	CI
Kolon TissueGene, Inc. announced that it expects to receive KRW 33 billion in funding from a group of investors	31/22/31	CI
Kolon TissueGene, Inc. announced that it has received $29.637774 million in funding from Kolon Corporation	29/22/29	CI
Kolon TissueGene, Inc. announced that it expects to receive $38.79881 billion in funding from Kolon Corporation and another investor	12/22/12	CI
Kolon TissueGene, Inc. Resumes TG-C Phase III Studies in the U.S	28/21/28	CI
Kolon TissueGene, Inc. announced that it has received KRW 29.140887075 billion in funding from Kolon Corporation	10/21/10	CI
Kolon TissueGene, Inc. to Expand Indications for TG-C	04/21/04	CI
Kolon TissueGene, Inc. announced that it expects to receive KRW 29.140887075 billion in funding from Kolon Corporation	02/21/02	CI
Kolon TissueGene, Inc. Announces Plans to Resume US Phase III Clinical Trial For TG-C	13/20/13	CI
Kolon TissueGene, Inc.(KOSDAQ:A950160) dropped from S&P Global BMI Index	23/19/23	CI
Kolon TissueGene, Inc. to Start US Phase III Clinical Trial for Invossa™	06/18/06	CI
TissueGene, Inc. has Changed its Name to Kolon TissueGene, Inc	16/18/16	CI
Kolon TissueGene, Inc.(KOSDAQ:A950160) added to S&P Global BMI Index	18/17/18	CI
Kolon TissueGene, Inc. has completed an IPO in the amount of KRW 202.5 billion.	05/17/05	CI
Kolon TissueGene, Inc. has filed an IPO.	14/17/14	CI
TissueGen® Inc. Names Lisa A. Fortier to its Scientific Advisory Board	27/17/27	CI
Kolon TissueGene, Inc. announced that it expects to receive $9.999995 million in funding	28/16/28	CI

Chart Kolon TissueGene, Inc.

Duration

Period

More charts

Company Profile

Kolon TissueGene, Inc. is a biopharmaceutical company. The Company develops cell-based therapies to treat osteoarthritis, orthopedic diseases, and other degenerative disorders. The Company's platform technology consists of a combination of allogeneic primary cells combined with genetically modified cells in one injectable therapeutic dose. The Company's lead product candidate is INVOSSA (TG-C), a cell and gene therapy for the treatment of osteoarthritis of the knee that has completed Phase II trials. TG-C is an allogeneic cell and gene therapy involving primary human chondrocytes (cartilage cells), which is delivered via one intra-articular injection into the knee. Its product pipelines fall under the category, such as osteoarthritis, musculoskeletal system disorder and vet medicine. The Company is also developing therapies for musculoskeletal system disorders, such as rheumatoid arthritis, meniscus, and spinal discs.

Sector

More about the company